Author

Rebecca L. Brouillette

Université de SherbrookeORCID 0000-0002-5466-9653Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Neuroscience· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 2 Research Focus:drug response / drug discovery· 1 Research Focus:host-pathogen & immune response· 1 Organism:human· 1 Organism:mouse· 1

Frequent Co-Authors

Christine E. MonaiD· 2 shared Élie Besserer‐OffroyiD· 2 shared Élora MidavaineiD· 2 shared Jean‐Michel LongpréiD· 2 shared Jérôme CôtéiD· 2 shared Philippe SarretiD· 2 shared Élizabeth Théberge· 1 shared Émile BreaultiD· 1 shared

Activity by Year

2023-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPharmacology & Toxicology

Christine E. MonaORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

A neurotensin receptor type 1-derived pepducin acts as a biased allosteric modulator to regulate target receptor function

Rebecca L. Brouillette, Frédérique Lussier, Émile Breault, Nathan Meneboo, Malihe Hassanzadeh, Victoria Tremblay, Magali Chartier, Élora Midavaine, Laurence Ulrich, Jérôme Côté, Véronique Blais, Christine E. Mona, Jean‐Michel Longpré, Michel Grandbois, Pierre‐Luc Boudreault, , Philippe Sarret

This paper describes a pepducin derived from NTS1 that acts as a biased allosteric modulator, preferentially activating G proteins over β-arrestin and inhibiting receptor internalization.

Acta Pharmaceutica Sinica B · Dec 31, 2025Peer-reviewedPharmacology & Toxicology

CCR2-targeting pepducins reduce T cell-nociceptor interaction driving bone cancer pain

Élora Midavaine, Rebecca L. Brouillette, Élizabeth Théberge, Christine E. Mona, Sakeen W. Kashem, Jérôme Côté, Vera Zeugin, Élie Besserer‐Offroy, Jean‐Michel Longpré, Éric Marsault, Philippe Sarret

The paper shows that CCR2-targeting pepducin PP101 reduces bone cancer pain by inhibiting T cell infiltration and neuroimmune communication in dorsal root ganglia without adverse effects.

bioRxiv · Sep 15, 2023 · PreprintNeuroscience